Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“FDA has determined that FAYUVI (rebisufligene etisparvovec-hopf), approved on September 17, 2026, manufactured by Ultragenyx Pharmaceutical Inc., meets the criteria for a priority review voucher.”
UnverifiableConfidence: LOW

Reasoning

The claim states that the FDA determined FAYUVI (rebisufligene etisparvovec-hopf), approved on September 17, 2026, meets criteria for a priority review voucher. Without any cited FDA announcements, press releases, or reputable sources, the claim cannot be substantiated.

On confidence: No supporting evidence was provided to confirm or refute the claim.

Important context

Priority review vouchers are granted by the FDA under specific programs, and any such determination would be documented in official FDA communications or reputable news outlets.

Evidence

No retrievable evidence was found; the verdict rests on the reporting itself and is marked accordingly.

Limitations

The assessment is limited to the absence of supplied evidence; no external sources were consulted.

Last verified:
Oct 6, 2026, 4:10 AM CDT
Pipeline:
2.1.0
Claim type:
Factual

Where this claim appeared

Issuance of Priority Review Voucher; Rare Pediatric Disease Product; FAYUVI (rebisufligene etisparvovec-hopf)

Federal Register · Drug Administration, Human Services Department, Food, Health